中国卫生标准管理
中國衛生標準管理
중국위생표준관리
CHINA HEALTH STANDARD MANAGEMENT
2015年
14期
101-102
,共2页
小儿肺炎支原体肺炎%红霉素%阿奇霉素
小兒肺炎支原體肺炎%紅黴素%阿奇黴素
소인폐염지원체폐염%홍매소%아기매소
Pneumonia mycoplasma pneumonia%Erythromycin%Azithromycin
目的:观察对比红霉素和阿奇霉素对小儿肺炎支原体肺炎的疗效。方法选取本院2014年2月~2015年2月收治的小儿肺炎支原体肺炎患儿150例,随机分为对照组与观察组各75人,所有患儿均给予止咳祛痰、退烧去热对症治疗,观察组给予阿奇霉素治疗,对照组给予红霉素治疗,观察两组患儿的疗效及不良反应。结果观察组的总有效率(92%)高于对照组的总有效率(76%);观察组不良反应发生率低于对照组,P<0.05,差异具有统计学意义。结论阿奇霉素对小儿肺炎支原体肺炎的治疗,相比红霉素具有疗效好、不良反应发生率低等优点,目前是治疗小儿肺炎支原体肺炎的一种较佳方案。
目的:觀察對比紅黴素和阿奇黴素對小兒肺炎支原體肺炎的療效。方法選取本院2014年2月~2015年2月收治的小兒肺炎支原體肺炎患兒150例,隨機分為對照組與觀察組各75人,所有患兒均給予止咳祛痰、退燒去熱對癥治療,觀察組給予阿奇黴素治療,對照組給予紅黴素治療,觀察兩組患兒的療效及不良反應。結果觀察組的總有效率(92%)高于對照組的總有效率(76%);觀察組不良反應髮生率低于對照組,P<0.05,差異具有統計學意義。結論阿奇黴素對小兒肺炎支原體肺炎的治療,相比紅黴素具有療效好、不良反應髮生率低等優點,目前是治療小兒肺炎支原體肺炎的一種較佳方案。
목적:관찰대비홍매소화아기매소대소인폐염지원체폐염적료효。방법선취본원2014년2월~2015년2월수치적소인폐염지원체폐염환인150례,수궤분위대조조여관찰조각75인,소유환인균급여지해거담、퇴소거열대증치료,관찰조급여아기매소치료,대조조급여홍매소치료,관찰량조환인적료효급불량반응。결과관찰조적총유효솔(92%)고우대조조적총유효솔(76%);관찰조불량반응발생솔저우대조조,P<0.05,차이구유통계학의의。결론아기매소대소인폐염지원체폐염적치료,상비홍매소구유료효호、불량반응발생솔저등우점,목전시치료소인폐염지원체폐염적일충교가방안。
Objective To observe the curative effect comparison of erythromycin and azithromycin on mycoplasma pneumoniae pneumonia in children.Methods A total of 150 cases of children with mycoplasma pneumonia in our hospital from 2014 February to February 2015,were randomly divided into control group and observation group of 75 people,al of them were given expectorant cough,fever to heat treatment,the observation group was given azithromycin treatment,the control group was given erythromycin treatment,curative effect and adverse reaction of two groups children were observed. ResultsThe total effective rate in the observation group(92%)was higher than that of the control group in the total efficiency(76%),the incidence of adverse reactions was significantly lower than the control group,P< 0.05,the difference was statisticaly significant.Conclusion The treatment of azithromycin on mycoplasma pneumoniae pneumonia in children,compared with erythromycin had good curative effect,adverse reaction rate is low,there is a better solution in the treatment of children with mycoplasma pneumonia.